Gene Expression – Talk Bio

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

6 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, BREAST-01, disease control rate, Gene Expression, Myers Squibb, ORR, PD-L1, PD-L1xVEGF-A, Phase 2 trial, Progression-Free Survival, pumitamig, ROSETTA, SABCS, TNBC, Triple Negative Breast Neoplasms

BioNTech; Bristol Myers Squibb; pumitamig; BNT327; PD-L1xVEGF-A bispecific antibody; Phase 2 trial; triple-negative breast cancer; TNBC; confirmed ORR; disease control rate; progression-free survival; PD-L1 expression; ROSETTA BREAST-01; SABCS

Keytruda Breaks New Ground with FDA Approval for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

2 weeks ago talkbio0Tagged Adjuvant Therapy, Approved, Clinical Trials, Event-Free Survival, Gene Expression, KEYNOTE-689 trial, Keytruda, Neoadjuvant Therapy, PD-L1, pembrolizumab, perioperative, Squamous cell carcinoma of the head and neck, United States Food and Drug Administration

Keytruda; pembrolizumab; perioperative treatment; head and neck squamous cell carcinoma; HNSCC; FDA approval; KEYNOTE-689 trial; neoadjuvant therapy; adjuvant therapy; PD-L1 expression; event-free survival; clinical trial

Wave Life Sciences’ WVE-N531 Shows Promise in Duchenne Muscular Dystrophy Treatment

9 months ago talkbio0Tagged Approved, Dystrophin, Gene Expression, Health Improvement, Muscle Tissue, Muscular Dystrophy, Duchenne, Phase 2 Clinical Trials, skipping, United States Food and Drug Administration, WVE-N531

Duchenne muscular dystrophy (DMD), WVE-N531, exon 53 skipping, Phase II trial, dystrophin expression, muscle health improvement, FDA approval

FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression

1 year ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, Immunotherapy, Keytruda, Malignant neoplasm of stomach, PD-L1, Tevimbra, United States Food and Drug Administration

FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra

FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression

1 year ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, nivolumab, PD-L1, PDCD1 gene, pembrolizumab, restrictions, tislelizumab, United States Food and Drug Administration

PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab

FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression

1 year ago talkbio0Tagged Biological Markers, Drug Approval, Esophageal Neoplasms, Gene Expression, inhibitors, Malignant neoplasm of stomach, Neoplasms, PD-L1, PDCD1 gene, United States Food and Drug Administration

FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval

Wave Life Sciences Reports Positive Interim Data for Duchenne Muscular Dystrophy Treatment

1 year ago talkbio0Tagged Clinical Trials, DMD, Does skip, Duchenne, Dystrophin, exon 53, FORWARD-53, Gene Expression, Interim, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Wave Life Sciences, WVE-N531

Wave Life Sciences, Duchenne Muscular Dystrophy, DMD, Exon 53 Skipping, WVE-N531, FORWARD-53 Clinical Trial, Interim Data, Muscle Health, Dystrophin Expression